Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.69 |
| ▸ | CA1 | P00915 | 1/20 | 0.69 |
| ▸ | CA2 | P00918 | 1/20 | 0.69 |
| ▸ | GLA | P06280 | 1/20 | 0.69 |
| ▸ | CA3 | P07451 | 1/20 | 0.69 |
| ▸ | CA4 | P22748 | 1/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.69 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 8/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 7/20 | 0.46 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.46 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phenol SCHEMBL8375278 | 0.94 | CA12 (0.69) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL7929451 | 0.91 | CA12 (0.65) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL7115665 | 0.88 | CA12 (0.61) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL5875310 | 0.88 | CA12 (0.61) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL2898082 | 0.88 | CA12 (0.61) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL21753960 | 0.88 | CA12 (0.69) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL2551294 | 0.86 | CA12 (0.58) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL11227306 | 0.85 | CA12 (0.65) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL9302707 | 0.85 | CA12 (0.65) | CA12CA1CA2GLACA3 | |
| Phenol SCHEMBL9396101 | 0.85 | CA12 (0.65) | CA12CA1CA2GLACA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275077-A1 | Methods of Obtaining Optically Active Epoxides and Vicinal Diols from Styrene Oxides | OXYRANE (UK) LIMITED (GB) | 2009-11-05 | — | — | US | disclosed |
| US-20070281339-A1 | Methods For Obtaining Optically Active Epoxides and Vicinal Diols From Styrene Oxides | OXYRANE UK LIMITED (GB) | 2007-12-06 | — | — | US | disclosed |
| EP-1756281-A2 | METHOD FOR THE PREPARATION OF OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM STYRENE EPOXIDES USING ENANTIOSELECTIVE EPOXIDE HYDROLASES DERIVED FROM YEASTS | CSIR (ZA) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005100569-A2 | METHODS FOR THE PREPARATION OF OPTICALLY ACTIVE EPOXIDES AND VICINAL DIOLS FROM STYRENE EPOXIDES USING ENANTIOSELECTIVE EPOXIDE HYDROLASES DERIVED FROM YEASTS | CSIR (ZA) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275077-A1 | Methods of Obtaining Optically Active Epoxides and Vicinal Diols from Styrene Oxides | EPHX2, EPHX1, DERA | CA12 2202/4885CA1 2078/4885CA2 2324/4885 |
| US-20070281339-A1 | Methods For Obtaining Optically Active Epoxides and Vicinal Diols From Styrene Oxides | DERA, ERG28, EPHX2 | CA12 3180/4885CA1 3174/4885CA2 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.